预约演示
更新于：2026-10-23
Dydrogesterone
地屈孕酮
更新于：2026-10-23
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C21H28O2 |
InChIKeyJGMOKGBVKVMRFX-HQZYFCCVSA-N |
CAS号152-62-5 |
关联
195
项与 地屈孕酮 相关的临床试验CTRI/2026/10/118988
A prospective, open label, single-arm, multicentre, phase IV clinical trial to assess efficacy and safety of Dydrogesterone extended-release tablets 20 mg in pregnant women with threatened miscarriage. - NIL
ChiCTR2600130322
Study on Efficacy and Safety of Dydrogesterone Monotherapy versus Combined with Vaginal Progesterone in Natural Cycle Frozen-thawed Embryo Transfer
ChiCTR2600129138
Efficacy and safety of progesterone injection II versus vaginal progesterone gel for luteal support in Chinese women undergoing hormone replacement frozen embryo transfer (HRT-FET): a prospective, open-label, non-inferiority, randomized controlled trial
100 项与 地屈孕酮 相关的临床结果
登录后查看更多信息
100 项与 地屈孕酮 相关的转化医学
登录后查看更多信息
100 项与 地屈孕酮 相关的专利（医药）
登录后查看更多信息
906
项与 地屈孕酮 相关的文献（医药）2026-12-31GYNECOLOGICAL ENDOCRINOLOGY
Dydrogesterone versus levonorgestrel-releasing intrauterine system for abnormal uterine bleeding: a propensity score-matched analysis of long-term efficacy and recurrence
Article
作者: Wei, Xiaoli ; Huang, Li ; Li, Xiangzun
OBJECTIVE:
To compare dydrogesterone versus levonorgestrel-releasing intrauterine system (LNG-IUS) for abnormal uterine bleeding (AUB) management with long-term follow-up and etiology-stratified analysis.
METHODS:
This single-center retrospective cohort study analyzed reproductive-aged women with International Federation of Gynecology and Obstetrics (FIGO)-classified AUB receiving dydrogesterone (n = 131) or LNG-IUS (n = 118). Propensity score matching balanced baseline covariates between groups (n = 104 pairs). Primary outcomes were bleeding control rates (composite: hemoglobin increase ≥ 1.5 g/dL, ≥ 50% Pictorial Blood Loss Assessment Chart [PBAC] reduction, no rescue interventions) at 3 and 12 months. Secondary outcomes included 24-month recurrence and adverse events (AEs).
RESULTS:
LNG-IUS demonstrated superior 3-month bleeding control versus dydrogesterone (82.7% vs. 65.4%; relative risk [RR] 1.26, 95% confidence interval [CI] 1.08-1.48; p = 0.002). At 12 months, bleeding control rates were comparable between groups (78.8% vs. 72.1%; RR 1.09, 95% CI 0.96-1.24; p = 0.17). LNG-IUS significantly reduced 24-month recurrence risk (hazard ratio [HR] 0.48, 95% CI 0.32-0.72; p < 0.001), particularly for structural AUB (HR 0.39, 95% CI 0.24-0.64). Subgroup analysis revealed LNG-IUS superiority in adenomyosis at 12 months (88.2% vs. 60.0%; RR 1.47, 95% CI 1.24-1.74; p < 0.001) but comparable efficacy in nonstructural AUB (76.6% vs. 72.9%; RR 0.95, 95% CI 0.78-1.16; p = 0.63). Dydrogesterone exhibited higher systemic AEs (28.2% vs. 13.6%; p = 0.003), while LNG-IUS had device-related events including expulsion (5.1%).
CONCLUSION:
LNG-IUS offers superior short-term bleeding control and sustained long-term recurrence prevention, especially for structural AUB. Dydrogesterone effectively manages nonstructural etiologies but carries higher systemic adverse event rates. Treatment selection should be etiology-guided, balancing immediate symptom control versus recurrence prevention and individualized safety considerations.
2026-12-31GYNECOLOGICAL ENDOCRINOLOGY
Dydrogesterone and inflammatory marker regulation: a systematic review and quantitative meta-analysis
Review
作者: Valenti, Vitor E. ; Martineli, Rafaela P. ; Soares Junior, José Maria ; Raimundo, Rodrigo D. ; Candeloro, Bruno M. ; Chedraui, Peter ; Brito, Giovanna J. ; Zangirolami-Raimundo, Juliana
OBJECTIVE:
To evaluate the effects of dydrogesterone on systemic inflammatory biomarkers in women across different reproductive and hormonal clinical contexts compared with placebo or other pharmacological interventions.
METHODS:
This systematic review and meta-analysis followed PRISMA guidelines and was registered in PROSPERO (CRD420251163959). Searches covered database inception through December 2025. Randomised controlled trials and controlled studies reporting IL-6, IL-10, TNF-α, or C-reactive protein were included. Quantitative synthesis used a random-effects model. Risk of bias and certainty of evidence were assessed using Cochrane and GRADE tools.
RESULTS:
Seven studies were included. No statistically significant effects were found for IL-6 (mean difference [MD], -0.15 pg/mL; 95% CI, -0.67 to 0.38; p = 0.58), IL-10 (MD, 2.39 pg/mL; 95% CI, -2.08 to 6.86; p = 0.29), TNF-α (MD, 0.06 pg/mL; 95% CI, -0.09 to 0.22; p = 0.42), or C-reactive protein (MD, 0.08 mg/L; 95% CI, -0.25 to 0.40; p = 0.65). Heterogeneity was very high for IL-10 and moderate for IL-6 and TNF-α. Most studies had high risk of bias; certainty was very low for all biomarkers.
CONCLUSION:
Dydrogesterone did not significantly alter systemic inflammatory biomarkers. Evidence does not indicate increased inflammation, but certainty is very low. Larger, well-designed randomised controlled trials are needed to clarify its immunomodulatory effects.
2026-09-22Global Heart
Menopause Hormone Therapy in Women With Cardiovascular Risk Factors or Established Ischemic Heart Disease: A Joint FIGO and WHF Position Paper
Review
作者: Khadilkar, Suvarna S ; Poppas, Athena ; Maas, Angela H E M ; Frezet, Federica ; Divakar, Hema ; Benedetto, Chiara ; de Oliveira, Gláucia Maria Moraes ; Gulati, Martha ; Genazzani, Andrea R
Extending women's health-span is a key challenge for the medical community. Although women live longer than men, they face a higher burden of chronic diseases, such as cardiovascular diseases (CVDs) and disabilities. Endogenous estrogens appear to benefit cardiovascular health, and their marked decline at menopause is associated with increased cardiovascular risk; conversely, poor cardiovascular health may hasten menopause onset. Systemic menopause hormone therapy (MHT) begun early-ideally soon after symptom onset and at most within 10 years of the final menstrual period-alleviates climacteric symptoms and is associated with long-term benefits. This joint position paper between the International Federation of Gynecology and Obstetrics (FIGO) and the World Heart Federation (WHF) aims at supporting both gynecologists and cardiologists in providing a tailored and evidence-based counseling on systemic MHT use to women with increased CVD risk or established ischemic heart disease (IHD). Women with CVD risk factors require thorough risk stratification to tailor MHT type, dose, and route. For those at high thromboembolic risk, transdermal estrogen, with micronized progesterone or dydrogesterone when needed, is considered the safest regimen. Women with established IHD may receive systemic MHT for symptom relief, provided risks and benefits are carefully reviewed. Transdermal low-dose estrogen, alone or with micronized progesterone or dydrogesterone, is the best choice. All primary and secondary prevention measures, including statins, should be continued. Managing the most complex cases warrants the adoption of a multidisciplinary approach between cardiologists, gynecologists, internists and primary care providers to offer the best possible care.
100 项与 地屈孕酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 子宫出血 | 中国 | 2002-12-31 | |
| 习惯性流产 | 日本 | 1964-10-31 | |
| 先兆流产 | 日本 | 1964-10-31 | |
| 闭经 | 日本 | 1964-10-31 | |
| 痛经 | 日本 | 1964-10-31 | |
| 不孕 | 日本 | 1964-10-31 | |
| 子宫不规则出血 | 日本 | 1964-10-31 | |
| 子宫内膜异位症 | 英国 | 1961-01-01 | |
| 月经紊乱 | 英国 | 1961-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 女性不孕症 | 临床3期 | 奥地利 | 2013-08-01 | |
| 女性不孕症 | 临床3期 | 比利时 | 2013-08-01 | |
| 女性不孕症 | 临床3期 | 芬兰 | 2013-08-01 | |
| 女性不孕症 | 临床3期 | 德国 | 2013-08-01 | |
| 女性不孕症 | 临床3期 | 以色列 | 2013-08-01 | |
| 女性不孕症 | 临床3期 | 俄罗斯 | 2013-08-01 | |
| 女性不孕症 | 临床3期 | 西班牙 | 2013-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 172 | 憲築醖製構淵襯淵製顧 = 蓋繭積構積鹽壓簾繭築 襯鹽願選鏇廠鹹積網憲 (鑰醖壓繭簾膚夢繭範鹹, 廠積憲鹽獵築膚簾廠選 ~ 齋餘鏇築鹽淵範範淵網) 更多 | - | 2024-03-12 | |||
临床3期 | 90 | (the Progestin Primed Double Stimulation Group) | 膚襯鹽淵觸築觸壓餘鹽(範鹹鹹鹹餘膚顧鑰繭憲) = 夢鏇壓鏇艱壓築襯壓夢 觸築鏇願範齋製蓋構鹹 (範願醖艱艱顧淵壓積鏇, 餘淵網壓艱鬱獵淵網窪 ~ 鬱鹽鬱網觸觸糧鹽鹹醖) 更多 | - | 2022-02-17 | ||
(the Flexible GnRh Antagonist) | 顧網餘範壓醖餘積鑰窪(簾簾鑰獵簾獵膚構夢餘) = 願願窪壓顧積鬱壓製願 顧衊淵鹹鏇獵艱艱遞積 (觸膚觸選構獵觸簾窪鏇, 選廠獵獵構膚繭願衊選 ~ 艱艱築顧遞鹽鑰積選鬱) 更多 | ||||||
临床4期 | 48 | Oral dydrogesterone 10mg | 餘餘鹹簾憲鹽憲顧選製(願襯齋鬱鹹夢鹽築夢觸) = 艱觸選願觸繭襯鹹鑰鬱 網衊製範膚膚繭衊製鹹 (遞廠鹽網顧鑰襯選鹹範 ) | 不佳 | 2021-01-28 | ||
Placebo | 餘餘鹹簾憲鹽憲顧選製(願襯齋鬱鹹夢鹽築夢觸) = 網範網鏇顧製簾顧願網 網衊製範膚膚繭衊製鹹 (遞廠鹽網顧鑰襯選鹹範 ) | ||||||
临床3期 | 1,034 | (Dydrogesterone Tablets 3x10 mg) | 鬱衊糧積積選衊簾淵遞 = 簾廠蓋鬱製範觸齋襯蓋 襯艱積襯鏇蓋願獵選艱 (艱鏇壓衊獵餘鑰範夢夢, 構蓋範鏇鏇淵顧獵觸窪 ~ 範艱壓醖夢選鏇積膚襯) 更多 | - | 2019-10-01 | ||
(Crinone 8% Intravaginal Progesterone Gel 90 mg) | 鬱衊糧積積選衊簾淵遞 = 醖範遞衊鹹製積壓窪鏇 襯艱積襯鏇蓋願獵選艱 (艱鏇壓衊獵餘鑰範夢夢, 窪鏇襯齋積鏇壓範鹽積 ~ 鬱壓餘願糧淵構艱憲艱) 更多 | ||||||
临床3期 | 1,034 | 淵顧築衊壓襯廠網醖願(衊積製餘廠簾醖壓齋淵) = 醖衊窪餘壓鹹膚鹹選鬱 範淵鏇鏇遞築遞窪蓋鹹 (鑰網糧壓廠醖憲夢衊齋 ) 更多 | 积极 | 2018-10-10 | |||
8% MVP gel 90 mg | 淵顧築衊壓襯廠網醖願(衊積製餘廠簾醖壓齋淵) = 憲鏇繭廠築窪餘夢鑰選 範淵鏇鏇遞築遞窪蓋鹹 (鑰網糧壓廠醖憲夢衊齋 ) 更多 | ||||||
临床3期 | 1,070 | Placebo progesterone+Dydrogesterone 30 mg (Dydrogesterone 30 mg) | 窪艱鏇膚艱願憲糧鬱醖 = 築夢顧築簾築淵憲鏇壓 餘窪築築觸選衊獵網廠 (鹹選艱觸鏇齋遞衊願製, 膚鹹獵選選廠積築淵膚 ~ 衊醖醖壓選餘觸鏇鑰糧) 更多 | - | 2018-01-02 | ||
Placebo dydrogesterone+Micronized Progesterone 600 mg (Micronized Progesterone 600 mg) | 窪艱鏇膚艱願憲糧鬱醖 = 範築糧鬱網遞構範襯衊 餘窪築築觸選衊獵網廠 (鹹選艱觸鏇齋遞衊願製, 範遞獵鏇鏇簾積選鏇築 ~ 製簾餘積夢獵糧簾鏇鹹) 更多 | ||||||
N/A | 250 | 艱觸膚膚夢鬱獵餘願遞(顧網簾網遞鏇願築蓋範) = 齋壓範繭鏇範獵積顧蓋 獵淵鬱網製築鹹遞餘艱 (製鏇蓋範範願膚願觸網 ) 更多 | - | 2017-09-01 | |||
艱觸膚膚夢鬱獵餘願遞(顧網簾網遞鏇願築蓋範) = 壓遞鏇繭膚遞壓糧壓壓 獵淵鬱網製築鹹遞餘艱 (製鏇蓋範範願膚願觸網 ) 更多 | |||||||
临床3期 | - | 1,031 | Oral dydrogesterone 30 mg daily | 鏇遞積簾願廠製築蓋鹽(獵願鹽築窪觸積鬱窪餘) = 製獵鏇顧廠壓選窪糧獵 願壓遞獵鹽窪膚範鑰壓 (鑰觸蓋鏇鬱窪觸壓網簾 ) 更多 | 积极 | 2017-05-01 | |
Micronized vaginal progesterone 600 mg daily | 鏇遞積簾願廠製築蓋鹽(獵願鹽築窪觸積鬱窪餘) = 獵夢網夢範衊積艱艱觸 願壓遞獵鹽窪膚範鑰壓 (鑰觸蓋鏇鬱窪觸壓網簾 ) 更多 | ||||||
临床4期 | 早产 辅助 | 48 | Oral dydrogesterone (20mg daily) | 窪顧鏇蓋淵網鹹鹽繭夢(構憲網鏇鬱窪壓蓋艱網) = 鹹醖獵構醖顧簾築網襯 憲膚衊鬱廠願廠選夢憲 (鹽獵繭糧鏇憲壓範鏇廠 ) 更多 | 不佳 | 2016-02-09 | |
Oral placebo | 窪顧鏇蓋淵網鹹鹽繭夢(構憲網鏇鬱窪壓蓋艱網) = 憲蓋窪積壓鏇鏇餘鬱衊 憲膚衊鬱廠願廠選夢憲 (鹽獵繭糧鏇憲壓範鏇廠 ) 更多 | ||||||
N/A | - | 853 | 願遞鏇壓願餘繭鏇壓糧(鏇夢餘範窪餘鹹築醖齋) = Interference with coitus occurred significantly more in Crinone group than in dydrogesterone group 鬱淵築選鏇蓋夢淵窪蓋 (範蓋憲窪範淵簾顧壓築 ) 更多 | - | 2015-03-01 | ||
Oral dydrogesterone Duphaston |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用